Navigation Links
Early antiretroviral treatment reduces viral reservoirs in HIV-infected teens
Date:3/4/2013

A study led by University of Massachusetts Medical School professor and immunologist Katherine Luzuriaga, MD, and Johns Hopkins Children's Center virologist Deborah Persaud, MD, highlights the long-term benefits of early antiretroviral therapy (ART) initiated in infants.

The study, presented on March 4 at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, shows that ART administered in early infancy can help curtail the formation of hard-to-treat viral sanctuaries reservoirs of "sleeper" cells responsible for reigniting infection in most HIV patients within weeks of stopping therapy.

The report describes nine teenagers, five of whom started ART around two months of age. Ultrasensitive testing showed dramatically lower copy numbers of viral DNA in the five teens who received ART within two months of exposure compared to the four teens who started treatment at a later age. In addition, serial testing demonstrated a small decay in the amounts of HIV DNA in the blood of the early-treated children over time. Moreover, using very sensitive techniques, the researchers were not able to recover HIV from the early-treated teens. In contrast, clinical tests detected viral hideouts in the late-treated teens. Four of the five early-treated children showed no HIV-specific antibodies on standard testing, but antibodies were detected in the blood of all four who started treatment late.

In a related report, Dr. Luzuriaga and Dr. Persaud reported on March 3 the case of an infant who underwent remission of HIV infection after receiving ART within 30 hours of birth. Altogether, these findings, the researchers say, can help pave the way toward achieving long-term viral suppression without treatment in children. Long-term viral suppression without treatment is an exceedingly rare phenomenon observed in so-called "elite controllers," HIV-infected patients whose immune systems are able to rein in viral replication and keep the virus at clinically undetectable levels even without treatment. HIV experts have long sought a way to help all HIV patients achieve such elite-controller status.

"Preventing mother-to-child transmission remains our primary goal but these studies provide the impetus for further studies aimed at curing children if they do acquire infection," says Luzuriaga.

Luzuriaga, a professor of pediatrics and molecular medicine at UMass Medical School, has been investigating maternal-fetal transmission and pediatric HIV since the disease was first identified. Her laboratory focuses on the immunopathogenesis of persistent viral infections in humans, and the development of prophylactic and therapeutic vaccine strategies for HIV.


'/>"/>

Contact: Lisa Larson
lisa.larson@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related biology news :

1. Artificial womb unlocks secrets of early embryo development
2. Mid-Atlantic suburbs can expect an early spring thanks to the heat of the big city
3. An early spring drives butterfly population declines
4. Hazy shades of life on early Earth
5. American Society of Plant Biologists honors early career women scientists
6. Early warning system for seizures could cut false alarms
7. A new gene thought to be the cause in early-onset forms of Alzheimers disease
8. Promising developments in early diagnosis and treatment of mesothelioma
9. Early detection techniques offer hope for improved outcomes in lung cancer patients
10. New study links air pollution and early death in the UK
11. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... ... June 22, 2016 , ... The Immigrant ... achievements and contributions to North Texas and the nation, recently held its annual ... community to the civic and economic vitality of North Texas. Proceeds from the ...
(Date:6/22/2016)... Fla. and ALBANY, N.Y. ... Sciences Corporation (Teewinot) and Albany Molecular Research, Inc. ... AMRI has licensed Teewinot,s technology to produce and ... analytical standard. The CBCA analytical standard is manufactured ... involve the expression of cannabinoid biosynthetic genes in ...
(Date:6/21/2016)... China , June 22, 2016 /PRNewswire/ ... 2 clinical trial for its novel patch product AB001 ... and clinically meaningful pain relief against placebo. Conducted at ... , the trial enrolled 146 patients with chronic ... analgesia against placebo at week-1 (p=0.024), (2) greater reduction ...
Breaking Biology Technology: